References
- Aggarwal S. What's fueling the biotechnology engine?. Nat Biotechnol 2007; 25:1097 - 1104
- Reichert JM. Number of mAbs entering clinical study nearly tripled in last decade. Tufts CSDD Impact Report 2008; 10:1 - 4
- FDA News Release 2004 at fda.gov/bbs/topics/NEWS/2004/NEW01024.html.
- Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23:712 - 719
- Hoag H. Tysabri's troubles return. Nat Biotechnol 2008; 26:1008 - 1061
- Presta L. Molecular engineering and design of monoclonal antibodies. Curr Opin Immunol 2008; 4:460 - 470
- Schneider CK, Kalinke U. Toward biolosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985 - 990
- Business Wire 2007;
- Bell G. Managing office-administered drugs: an economist's perspective. JMCM 2007; 10:34 - 38
- Lee TH, Emanuel EJ. Tier 4 drugs and the fraying of the social compact. N Engl J Med 2008; 359:333 - 335
- Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bavacizumab (Avastin): modeling cost effectiveness. Br J Ophthalmol 2007; 91:1244 - 1246
- Allison M. Trouble at the Office. Nature Biotech 2008; 26:967 - 969
- Jain E, Kumar A. Upstream processes in antibody production: evaluation of critical parameters. Biotechnol Adv 2008; 26:46 - 72
- Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B 2007; 848:8 - 18
- Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006; 24:1591 - 1597
- Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA. Considerations for the development of monoclonal therapeutic antibodies. Curr Opin Immunol 2008; 4:493 - 499
- Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6:349 - 356
- Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109:170 - 179
- Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T-cell-engaging antibody. Science 2008; 321:974 - 977
- Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P, Lindhofer H. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 X anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 2008; 123:1181 - 1189
- Damle NK. Antibody-drug conjugates ace the tolerability test. Nat Biotechnol 2008; 26:884 - 885
- Rich MW. From clinical trials to clinical practice: bridging the GAP. JAMA 2002; 287:1321 - 1323
- Ramsey S, Scoggins J. Commentary: Practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology. Oncologist 2008; 13:925 - 929
- Table of valid genomic biomarkers in the context of approved drug labels FDA website at fda.gov/cder/genomic_biomarkers_table.htm.
- De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508 - 515
- Russo MJ, Balekdjian D. Weighing the outcomes. Nat Biotechnol 2008; 26:173 - 182